Your NAD+ pills cannot enter your cells: the science is public

You are probably taking NAD+ supplements wrong. Not "wrong dose" or "wrong brand" wrong. Structurally, biochemically wrong: the NAD+ molecule itself cannot cross your cell membranes. Your body has no transporter for it. Every capsule of direct NAD+ you swallow gets shredded by your gut and liver before it reaches a single mitochondrion.

The NAD+ supplement market crossed $3.4 billion in 2024, driven by longevity influencers, biohacking podcasts, and the seductive promise that boosting one molecule could reverse aging. But a growing body of peer-reviewed research reveals an uncomfortable truth: most people spending $50 to $150 per month on these supplements are paying for expensive urine.

NAD+ supplements cannot enter your cells, so what happens instead?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential to every living cell. It fuels mitochondrial energy production, powers DNA repair enzymes called sirtuins, and declines with age. That much is real. The problem starts when you try to replenish it from outside.

Your body cannot absorb intact NAD+ through the gut. Instead, the supplement industry pivoted to "precursors," molecules your body theoretically converts into NAD+. The two leading candidates are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both raise NAD+ levels in blood tests. Both carry a critical asterisk.

A 2023 review published in Frontiers in Nutrition found that oral NMN undergoes "extensive first-pass metabolism in the liver," with nearly all ingested NMN converted into plain nicotinamide (NAM) before reaching peripheral tissues. A parallel review in Science Advances concluded that many clinical trials "do not provide evidence that oral supplementation raised tissue NAD+ levels," despite blood markers looking promising.

In plain language: the molecule shows up on your blood test, but it may never reach the cells where aging actually happens.

The FDA pulled NMN off shelves, then changed its mind

In late 2022, the FDA classified NMN as an investigational new drug, effectively banning it from supplement shelves. MetroBiotech had filed NMN for drug trials before it was ever sold as a supplement, triggering the "drug preclusion clause" of federal law. Amazon and major retailers stripped their listings overnight.

The supplement industry fought back. The Natural Products Association filed a lawsuit, and after years of legal pressure, the FDA reversed course in September 2025, reinstating NMN as a lawful dietary supplement. The molecule bounced back onto every wellness shelf. But the regulatory saga exposed something the marketing never mentions: no company had enough clinical evidence to defend NMN as a proven health product. Its return was a legal victory, not a scientific one.

The cancer question nobody wants to discuss

Here is where NAD+ supplements collide with a genuinely unsettling finding. A 2021 review in Aging and Disease documented that elevated NAD+ levels can fuel tumor growth. Cancer cells are energy-hungry, and NAD+ is their preferred currency. The review found that "high levels of NAD bestow therapy resistance to cancers," meaning supplementation could theoretically make existing tumors harder to treat.

The authors specifically cautioned anyone with a personal or family history of cancer to consult a physician before supplementing. Yet the typical supplement marketing targets people over 40, the exact demographic where undiagnosed early-stage cancers are most common. This does not mean NAD+ precursors cause cancer. The evidence is preliminary and mostly from animal models. But the fact that the longevity supplement industry largely ignores this data point while marketing heavily to aging populations reflects the wellness industry's pattern of selling anxiety as self-care.

What actually works (and what does not)

The honest summary: NR and NMN are safe at standard doses. They reliably raise NAD+ in blood. Whether that translates into the lifespan extension, cognitive sharpness, or metabolic improvement promised on supplement labels remains unproven in humans.

Multiple randomized controlled trials found "no effect of NR for improving common clinical outcomes such as insulin sensitivity, energy expenditure, or exercise capacity," according to the Frontiers review. The benefits seen in mice used doses and durations far exceeding anything practical for humans.

Meanwhile, compounds that actually cross the blood-brain barrier and show measurable cognitive effects in humans exist at a fraction of the cost, like a $0.12 dye that actually crosses the blood-brain barrier. And the longevity research generating the most excitement has nothing to do with supplements. It involves age-reversal trials the supplement industry downplays and a fatty acid activating 24 longevity pathways for $1 a day.

The real question is not whether NAD+ matters

NAD+ absolutely matters. It is foundational to cellular health. The question is whether swallowing a capsule and watching a blood marker rise is the same as meaningfully changing what happens inside your cells. Right now, the science says: probably not. The $3.4 billion industry selling you the opposite has not earned the confidence it demands.

Before spending another dollar on NAD+ precursors, ask for the one thing no supplement company wants to show you: a human clinical trial demonstrating improved health outcomes, not just improved blood numbers.

---

Related Reading:

• 130,000 patients expose melatonin's hidden heart failure risk
• The $0.03 gym supplement that outperforms nootropics